How would you spend 192 Million Euros on Biotech and Medical Devices?




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: How would you spend 192 Million Euros on Biotech and Medical Devices?
Released on: August 31, 2014. © PTV
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    During BioTrinity 2014 Olivier Litzka, Partner, Edmond de Rothschild Investment Partners talks to Fintan Walton about BioDiscovery IV and how they will be investing the fund.
  • Summary
  • Transcript
  • Participants
  • Company
During BioTrinity 2014 Olivier Litzka, Partner, Edmond de Rothschild Investment Partners talks to Fintan Walton about BioDiscovery IV and how they will be investing the fund.
During BioTrinity 2014 Olivier Litzka, Partner, Edmond de Rothschild Investment Partners talks to Fintan Walton about BioDiscovery IV and how they will be investing the fund.
Olivier Litzka
Edmond de Rothschild Investment Partners
Edmond de Rothschild Investment Partners
dmond de Rothschild Investment Partners has participated for more than 20 years in the development and dynamism of European SMEs. Helping to accelerate growth, our 18 investors build genuine partnerships with entrepreneurs and directly contribute to improving the performance of the companies in which they invest. Edmond de Rothschild Investment Partners provides institutional investors with access to high-growth segments which require development capital skills and considerable sector-specific expertise. Managing more than €800 million, and benefiting from the expertise and networks of the Compagnie Financière Edmond de Rothschild, Edmond de Rothschild Investment Partners operates in three business segments with promising futures Edmond de Rothschild Investment Partners is a management company approved by the French Financial Markets Authority (AMF approval: GP 02029) which manages more than €800 million through specialized funds. The three segments in which we operate are Development Capital Mid Caps, private equity in Life Sciences and Development Capital Small Caps.